| 000 | 01443 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250513093804.0 | ||
| 264 | 0 | _c19961010 | |
| 008 | 199610s 0 0 eng d | ||
| 022 | _a0160-9289 | ||
| 024 | 7 |
_a10.1002/clc.4960190517 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaron, D J | |
| 245 | 0 | 0 |
_aNonlipid primary and secondary prevention strategies for coronary heart disease. _h[electronic resource] |
| 260 |
_bClinical cardiology _cMay 1996 |
||
| 300 |
_a419-23 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAnticoagulants _xtherapeutic use |
| 650 | 0 | 4 | _aBlood Glucose |
| 650 | 0 | 4 |
_aCalcium Channel Blockers _xtherapeutic use |
| 650 | 0 | 4 |
_aCoronary Disease _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aEstrogen Replacement Therapy |
| 650 | 0 | 4 | _aExercise |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGuidelines as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xtherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPrimary Prevention _xeconomics |
| 650 | 0 | 4 | _aSmoking Cessation |
| 650 | 0 | 4 | _aWeight Loss |
| 773 | 0 |
_tClinical cardiology _gvol. 19 _gno. 5 _gp. 419-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/clc.4960190517 _zAvailable from publisher's website |
| 999 |
_c8720760 _d8720760 |
||